Synthesis and mechanistic studies of a novel homoisoflavanone inhibitor of endothelial cell growth

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Basavarajappa, Halesha D ^a   Lee, Bit ^b   Fei, Xiang ^b   Lim, Daesung ^b   Callaghan, Breedge ^a   Mund, Julie A ^a,c   Case, Jamie ^a,c   Rajashekhar, Gangaraju ^a   Seo, Seung Yong ^b   Corson, Timothy W ^a,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Gachon University   (South Korea)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIHYDROXY 3 (3 HYDROXY 4 METHOXYBENZYL) 7 METHOXYCHROMAN 4 ONE; CYCLOOXYGENASE 2; FLAVANONE DERIVATIVE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SH 11052; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ERYTHROPOIETIN; ISOFLAVONE DERIVATIVE; VASCULOTROPIN A;

ANGIOGENESIS; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; INFLAMMATION; MICROVASCULAR ENDOTHELIAL CELL; PROTEIN DEGRADATION; RETINAL MICROVASCULAR ENDOTHELIAL CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYNTHESIS;

CELL CYCLE; CELL LINE; CELL PROLIFERATION; ENDOTHELIAL CELLS; ERYTHROPOIETIN; HUMANS; ISOFLAVONES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899701416     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095694     Document Type: Article

References (65)

1. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, et al. (2008) Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27: 331-371.
2. Fine SL, Berger JW, Maguire MG, Ho AC (2000) Age-related macular degeneration. New Engl J Med 342: 483-492. (Pubitemid 30100237)
3. Faia LJ, Trese MT (2011) Retinopathy of prematurity care: screening to vitrectomy. Int Ophthalmol Clin 51: 1-16.
4. Gilbert C, Rahi J, Eckstein M, O'Sullivan J, Foster A (1997) Retinopathy of prematurity in middle-income countries. Lancet 350: 12-14.
5. Folk JC, Stone EM (2010) Ranibizumab therapy for neovascular age-related macular degeneration. New Engl J Med 363: 1648-1655.
6. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, et al. (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116: 57-65.
7. Hodge W, Brown A, Kymes S, Cruess A, Blackhouse G, et al. (2010) Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation. Can J Ophthalmol 45: 223-230.
8. Mitchell P, Annemans L, White R, Gallagher M, Thomas S (2011) Cost effectiveness of treatments for wet age-related macular degeneration. PharmacoEconomics 29: 107-131.
9. Lux A, Llacer H, Heussen FM, Joussen AM (2007) Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 91: 1318-1322. (Pubitemid 47492865)
10. Oh H, Takagi H, Takagi C, Suzuma K, Otani A, et al. (1999) The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 40: 1891-1898. (Pubitemid 29365148)
11. Yoshida A, Yoshida S, Khalil AK, Ishibashi T, Inomata H (1998) Role of NF-κB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci 39: 1097-1106. (Pubitemid 28247343)
12. Sagar SM, Yance D, Wong RK (2006) Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1. Curr Oncol 13: 14-26.
13. Sagar SM, Yance D, Wong RK (2006) Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. Curr Oncol 13: 99-107.
14. Bid HK, Oswald D, Li C, London CA, Lin J, et al. (2012) Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. PLoS ONE 7: 17.
15. Lai SL, Cheah SC, Wong PF, Noor SM, Mustafa MR (2012) In vitro and in vivo anti-angiogenic activities of Panduratin A. PLoS ONE 7: 30.
16. Kim JH, Lee YM, Ahn EM, Kim KW, Yu YS (2009) Decursin inhibits retinal neovascularization via suppression of VEGFR-2 activation. Mol Vis 15: 1868-1875.
17. Roskoski R Jr (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356: 323-328.
18. Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ, et al. (2004) Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 7: 115-122. (Pubitemid 39491728)
19. Zhang MS, Peng SW, Wang W (2010) Macro research on growth and development of Cremastra appendiculata (D. Don.) Makino (Orchidaceae). J Med Plant Res 4: 1837-1842.
20. Ikeda Y, Nonaka H, Furumai T, Igarashi Y (2005) Cremastrine, a pyrrolizidine alkaloid from Cremastra appendiculata. J Nat Prod 68: 572-573. (Pubitemid 40586321)
21. Shim JS, Kim JH, Lee J, Kim SN, Kwon HJ (2004) Anti-angiogenic activity of a homoisoflavanone from Cremastra appendiculata. Planta Med 70: 171-173. (Pubitemid 38299781)
22. Crouch NR, Bangani V, Mulholland DA (1999) Homoisoflavanones from three South African Scilla species. Phytochemistry 51: 943-946. (Pubitemid 29320874)
23. Kim JH, Yu YS, Jun HO, Kwon HJ, Park KH, et al. (2008) Inhibition of choroidal neovascularization by homoisoflavanone, a new angiogenesis inhibitor. Mol Vis 14: 556-561. (Pubitemid 351472355)
24. Kim JH, Kim KH, Yu YS, Kim YM, Kim KW, et al. (2007) Homoisoflavanone inhibits retinal neovascularization through cell cycle arrest with decrease of cdc2 expression. Biochem Biophys Res Commun 362: 848-852. (Pubitemid 47390651)
25. Ponce ML (2001) In vitro matrigel angiogenesis assays. Methods Mol Med 46: 205-209.
26. Fujii M, Egawa K, Hirai Y, Kondo M, Fujii K, et al. (2009) Dihydrochalcone designed from methylophiopogonanone B strongly inhibits Hypoxia-Inducible Factor (Hif)-1 α activity. Heterocycles 78: 2061-2065.
27. Zhang L, Zhang WG, Kang J, Bao K, Dai Y, et al. (2008) Synthesis of (+/2) homoisoflavanone and corresponding homoisoflavane. J Asian Nat Prod Res 10: 909-913.
28. Poisson T, Gembus V, Dalla V, Oudeyer S, Levacher V (2010) Organocatalyzed enantioselective protonation of silyl enol ethers: Scope, limitations, and application to the preparation of enantioenriched homoisoflavones. J Org Chem 75: 7704-7716.
29. Kawasaki M, Toyooka N, Matsui Y, Tanaka A, Goto M, et al. (2005) Asymmetric synthesis of homoisoflavanone using lipase-catalyzed reaction. Heterocycles 65: 761-765.
30. Rao VM, Damu GLV, Sudhakar D, Siddaiah V, Rao CV (2008) New efficient synthesis and bioactivity of homoisoflavonoids. Arkivoc 11: 285-294.
31. Chen DZ, Yang J, Yang B, Wu YS, Wu T (2010) Total synthesis of baicalein. J Asian Nat Prod Res 12: 124-128.
32. Vanderslice P, Munsch CL, Rachal E, Erichsen D, Sughrue KM, et al. (1998) Angiogenesis induced by tumor necrosis factor-α is mediated by α4 integrins. Angiogenesis 2: 265-275. (Pubitemid 128513126)
33. Klein S, de Fougerolles AR, Blaikie P, Khan L, Pepe A, et al. (2002) α5β1 integrin activates an NF-κB-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol 22: 5912-5922. (Pubitemid 34815839)
34. Rajashekhar G, Willuweit A, Patterson CE, Sun P, Hilbig A, et al. (2006) Continuous endothelial cell activation increases angiogenesis: evidence for the direct role of endothelium linking angiogenesis and inflammation. J Vasc Res 43: 193-204. (Pubitemid 43248001)
35. Rajashekhar G, Kamocka M, Marin A, Suckow MA, Wolter WR, et al. (2011) Pro-inflammatory angiogenesis is mediated by p38 MAP kinase. J Cell Physiol 226: 800-808.
36. Tomita K, Chikumi H, Tokuyasu H, Yajima H, Hitsuda Y, et al. (1999) Functional assay of NF-κB translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline. Naunyn Schmiedebergs Arch Pharmacol 359: 249-255. (Pubitemid 29210954)
37. Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296: 1634-1635. (Pubitemid 34579145)
38. Liu RY, Fan C, Liu G, Olashaw NE, Zuckerman KS (2000) Activation of p38 mitogen-activated protein kinase is required for tumor necrosis factor-asupported proliferation of leukemia and lymphoma cell lines. J Biol Chem 275: 21086-21093.
39. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, et al. (1997) Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272: 21096-21103. (Pubitemid 27373968)
40. Natarajan K, Singh S, Burke TR Jr, Grunberger D, Aggarwal BB (1996) Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB. Proc Natl Acad Sci U S A 93: 9090-9095. (Pubitemid 26282023)
41. Zhang F, Yu W, Hargrove JL, Greenspan P, Dean RG, et al. (2002) Inhibition of TNF-α induced ICAM-1, VCAM-1 and E-selectin expression by selenium. Atherosclerosis 161: 381-386. (Pubitemid 34219191)
42. Rajashekhar G, Grow M, Willuweit A, Patterson CE, Clauss M (2007) Divergent and convergent effects on gene expression and function in acute versus chronic endothelial activation. Physiol Genomics 31: 104-113. (Pubitemid 47443852)
43. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, et al. (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56: 549-580. (Pubitemid 39658463)
44. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, et al. (1999) NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85.
45. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, et al. (1997) Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor α-dependent angiogenesis. Mol Cell Biol 17: 4015-4023. (Pubitemid 27281877)
46. Chen J, Smith LE (2007) Retinopathy of prematurity. Angiogenesis 10: 133-140. (Pubitemid 46440629)
47. Economopoulou M, Bdeir K, Cines DB, Fogt F, Bdeir Y, et al. (2005) Inhibition of pathologic retinal neovascularization by α-defensins. Blood 106: 3831-3838. (Pubitemid 41739020)
48. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9: 653-660.
49. Royds JA, Dower SK, Qwarnstrom EE, Lewis CE (1998) Response of tumour cells to hypoxia: role of p53 and NFκB. Mol Pathol 51: 55-61. (Pubitemid 28261243)
50. Ratner M (2004) Genentech discloses safety concerns over Avastin. Nat Biotechnol 22: 1198.
51. Friedlander M (2009) Combination angiostatic therapies: targeting multiple angiogenic pathways. Retina 29: S27-29.
52. Bhasin M, Yuan L, Keskin DB, Otu HH, Libermann TA, et al. (2010) Bioinformatic identification and characterization of human endothelial cellrestricted genes. BMC Genomics 11: 342.
53. du Toit K, Elgorashi EE, Malan SF, Drewes SE, van Staden J, et al. (2005) Anti-inflammatory activity and QSAR studies of compounds isolated from Hyacinthaceae species and Tachiadenus longiflorus Griseb. (Gentianaceae). Bioorg Med Chem 13: 2561-2568. (Pubitemid 40341659)
54. Hur S, Lee YS, Yoo H, Yang JH, Kim TY (2010) Homoisoflavanone inhibits UVB-induced skin inflammation through reduced cyclooxygenase-2 expression and NF-κB nuclear localization. J Dermatol Sci 59: 163-169.
55. Tak PP, Firestein GS (2001) NF-κB: a key role in inflammatory diseases. J Clin Invest 107: 7-11. (Pubitemid 32047405)
56. Yoshida A, Yoshida S, Ishibashi T, Kuwano M, Inomata H (1999) Suppression of retinal neovascularization by the NF-κB inhibitor pyrrolidine dithiocarbamate in mice. Invest Ophthalmol Vis Sci 40: 1624-1629. (Pubitemid 29252358)
57. Omar HA, Arafa el SA, Salama SA, Arab HH, Wu CH, et al. (2013) OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways. Toxicol Appl Pharmacol 272: 616-624.
58. Meyer RD, Latz C, Rahimi N (2003) Recruitment and activation of phospholipase Cγ1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells. J Biol Chem 278: 16347-16355. (Pubitemid 36799761)
59. Raffioni S, Thomas D, Foehr ED, Thompson LM, Bradshaw RA (1999) Comparison of the intracellular signaling responses by three chimeric fibroblast growth factor receptors in PC12 cells. Proc Natl Acad Sci U S A 96: 7178-7183. (Pubitemid 29299635)
60. Lallena MJ, Diaz-Meco MT, Bren G, Paya CV, Moscat J (1999) Activation of IκB kinase β by protein kinase C isoforms. Mol Cell Biol 19: 2180-2188.
61. Kang YJ, Mbonye UR, DeLong CJ, Wada M, Smith WL (2007) Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 46: 108-125. (Pubitemid 46661865)
62. Maehara K, Hasegawa T, Isobe KI (2000) A NF-κB p65 subunit is indispensable for activating manganese superoxide: dismutase gene transcription mediated by tumor necrosis factor-a. J Cell Biochem 77: 474-486. (Pubitemid 30230601)
63. Yang HT, Papoutsopoulou S, Belich M, Brender C, Janzen J, et al. (2012) Coordinate regulation of TPL-2 and NF-κB signaling in macrophages by NFκB1 p105. Mol Cell Biol 32: 3438-3451.
64. Webster GA, Perkins ND (1999) Transcriptional cross talk between NF-κB and p53. Mol Cell Biol 19: 3485-3495. (Pubitemid 29193808)
65. Gupta SC, Sundaram C, Reuter S, Aggarwal BB (2010) Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 1799: 775-787.